While an mRNA vaccine is still missing, 2021 saw Indian companies strike alliances, battle legal action and gain funding while the regulator played a crucial enabling role in the run up to the approval of eight COVID-19 vaccines from zero in 2020.

Also, AstraZeneca presents more promising data for its COVID-19 antibody cocktail Evusheld and Novavax says its vaccine is able to neutralize the Omicron variant. 

In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.

BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.